Teva Pharmaceutical share price logo

Teva Pharmaceutical

NYSE: TEVA

Large Cap

$39.04

-0.15

(-0.38%)

Live

as on

Teva Pharmaceutical Stock Performance

as on September 19, 2026 at 5:13 am IST

  • Day's Low

    Day's High

    $38.66
    $39.24
    downward going graph

    0.97%

    Downside

    0.51%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $18.21
    $39.70
    downward going graph

    53.36%

    Downside

    1.69%

    Upside

    downward going graph

Teva Pharmaceutical share price movements today

Previous Close
$39.19
Open
$38.91
Volume
2.0M
Market Cap
$45.1B
Day's Low - High
$38.66 - $39.24
52 Week Low - High
$18.21 - $39.70

Teva Pharmaceutical Historical Returns

1 Month Return
+ 7.14 %
3 Month Return
+ 24.49 %
1 Year Return
+ 112.41 %
3 Year Return
+ 271.82 %
5 Year Return
+ 335.93 %

Teva Pharmaceutical Stock Fundamentals & Key Indicators

Check Teva Pharmaceutical market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$45.1B

EPS (TTM)

0.63

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.72%

PE Ratio (TTM)

58.05

Industry PE ratio

14.49

PEG Ratio

0.10554211832611832

EBITDA

2.6B

Revenue (TTM)

17.3B

Profit Margin

52.46%

Return On Equity TTM

9.18%

Teva Pharmaceutical Stock Valuation

Track how Teva Pharmaceutical P/E has moved over time to understand its valuation trends.

Teva Pharmaceutical in the last 5 years

  • Overview

  • Trends

Lowest (-20.90x)

December 31, 2023

Industry (14.49x)

December 31, 2025

Today (25.37x)

December 31, 2025

Highest (25.37x)

December 31, 2025

LowHigh

Today’s Price to Earnings Ratio: 25.37x

Teva Pharmaceutical vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Teva Pharmaceutical with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
SELL$45.1B335.93%58.0552.46%0.00%
BUY$21.3B148.54%16.5586.14%0.00%
HOLD$19.1B26.23%-47.5834.83%2.82%
BUY$40.0BNA18.7765.57%1.35%
BUY$30.3B-63.21%12.0170.87%2.86%

Stock Returns calculator for Teva Pharmaceutical Stock including INR - Dollar returns

The Teva Pharmaceutical stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Teva Pharmaceutical investment value today

Current value as on today

₹2,31,199

Returns

₹1,31,199

(+131.2%)

Returns from Teva Pharmaceutical Stock

₹1,11,599 (+111.6%)

Dollar Impact

₹19,600 (+19.6%)

Analyst Recommendation on Teva Pharmaceutical Stock

Based on 9 analysts

SELL

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 9 analysts, 100% of analysts recommend a 'SELL' rating for Teva Pharmaceutical. Average target price of $42

Teva Pharmaceutical Share Price Target

Get share price movements and forecasts by analysts on Teva Pharmaceutical.

What analysts predicted

7.05%UPSIDE

Target Price

$42

Current Price

$39.04

Analyzed by

9 Analysts

Target

$42.00

Teva Pharmaceutical target price $42, a slight upside of 7.05% compared to current price of $39.04. According to 9 analysts rating.

Indian Investors' Interest in Teva Pharmaceutical Stock

Search interest for Teva Pharmaceutical Stock has increased by 71% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:71% versus previous 30 day period

Teva Pharmaceutical Quarterly Profit & Loss

All numbers in Millions USD

Jun 2025
Jun 2025
Sep 2025
Sep 2025
Dec 2025
Dec 2025
Mar 2026
Mar 2026
Jun 2026
Jun 2026
Total Revenue
4,176
4,176
4,480
4,480
4,711
4,711
3,981
3,981
4,142
4,142
Gross Profit
2,102
2,102
2,304
2,304
2,656
2,656
1,972
1,972
2,153
2,153
Operating Income
455
455
882
882
300
300
652
652
149
149
EBITDA
657
657
1,104
1,104
632
632
877
877
-19
-19
Interest Expense
203
203
209
209
292
292
201
201
200
200
Depreciation
251
251
249
249
260
260
239
239
241
241
Income Before Tax
204
204
648
648
91
91
436
436
-455
-455
Income Tax Expense
-78
-78
214
214
-390
-390
67
67
121
121
Net Income
282
282
433
433
480
480
369
369
-576
-576
Net Profit Margin
50.34%
50.34%
51.43%
51.43%
56.38%
56.38%
49.54%
49.54%
51.98%
51.98%

Teva Pharmaceutical Annual Profit & Loss

All numbers in Millions USD

Dec 2021
Dec 2021
Dec 2022
Dec 2022
Dec 2023
Dec 2023
Dec 2024
Dec 2024
Dec 2025
Dec 2025
Total Revenue
15,878
15,878
14,925
14,925
15,845
15,845
16,544
16,544
17,257
17,257
Gross Profit
7,594
7,594
6,973
6,973
7,645
7,645
8,063
8,063
8,938
8,938
Operating Income
1,716
1,716
-2,197
-2,197
433
433
-303
-303
2,157
2,157
EBITDA
4,409
4,409
-925
-925
1,558
1,558
4,431
4,431
3,141
3,141
Interest Expense
891
891
930
930
1,029
1,029
941
941
916
916
Depreciation
1,330
1,330
1,308
1,308
1,153
1,153
1,059
1,059
1,002
1,002
Income Before Tax
667
667
-3,142
-3,142
-622
-622
-1,283
-1,283
1,238
1,238
Income Tax Expense
211
211
-643
-643
-7
-7
676
676
-180
-180
Net Income
417
417
-2,446
-2,446
-559
-559
-1,639
-1,639
1,410
1,410
Net Profit Margin
47.83%
47.83%
46.72%
46.72%
48.25%
48.25%
48.74%
48.74%
51.79%
51.79%

Teva Pharmaceutical Quarterly Cash Flow

All numbers in Millions USD

Jun 2025
Jun 2025
Sep 2025
Sep 2025
Dec 2025
Dec 2025
Mar 2026
Mar 2026
Jun 2026
Jun 2026
Net Income
283
283
434
434
481
481
369
369
-575
-575
Operating Cash Flow
227
227
369
369
1,158
1,158
-40
-40
411
411
Investing Cash Flow
236
236
135
135
165
165
229
229
-491
-491
Financing Cash Flow
6
6
-453
-453
40
40
13
13
-1
-1
Change in Cash
464
464
42
42
1,353
1,353
185
185
-86
-86

Teva Pharmaceutical Annual Cash Flow

All numbers in Millions USD

Dec 2021
Dec 2021
Dec 2022
Dec 2022
Dec 2023
Dec 2023
Dec 2024
Dec 2024
Dec 2025
Dec 2025
Net Income
456
456
-2,499
-2,499
-615
-615
-1,959
-1,959
1,418
1,418
Operating Cash Flow
798
798
1,590
1,590
1,368
1,368
1,247
1,247
1,649
1,649
Investing Cash Flow
1,523
1,523
656
656
968
968
792
792
737
737
Financing Cash Flow
-2,172
-2,172
-1,487
-1,487
-1,913
-1,913
-1,791
-1,791
-2,151
-2,151
Change in Cash
21
21
636
636
393
393
73
73
256
256

Mutual Funds that own Teva Pharmaceutical Stock

Check out the Mutual Funds with significant holdings in Teva Pharmaceutical.

Funds
Holdings
Shares Held
INVESTMENT MANAGERS SERIES TRUST
1.150253%
13403860
Fidelity Investment Trust
0.657156%
7657817
Fidelity Contrafund
0.636122%
7412711
New Economy Fund
0.424198%
4943168
Fidelity Concord Street Trust
0.390275%
4547862

Global Institutional Holdings in Teva Pharmaceutical

Funds
Holdings
David Gerald Greenspan
0.68%
Larry Robbins
0.44%
Lee Ainslie
0.37%
Andreas Halvorsen
0.22%
UBS
0.17%

Teva Pharmaceutical News & Key Events

  • img

    Today's Timeline - 16 September

    Wed, 05:30 PM

    -

    Teva launches LongActingImpact.com to support clinicians in schizophrenia care with evidence-based resources.

    Thu, 02:19 AM

    -

    Teva announces €1.5 billion and $3.2 billion senior notes offering to refinance existing debt and fund corporate purposes.

Insights on Teva Pharmaceutical

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Teva Pharmaceutical Industries Limited has shown positive revenue growth over the last two quarters. Revenue increased from $3.98 billion to $4.14 billion, reflecting an average growth rate of 3.9% per quarter.

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, TEVA has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, TEVA stock has moved up by 5.7%

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, TEVA has outperformed top 5 stocks with highest market-cap in its industry

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Teva Pharmaceutical Industries Limited has experienced a decline in net profit over the last three quarters. The net profit decreased from $480.0 million to -$576.0 million, indicating a significant downturn. On average, the profit decreased by 139.6% each quarter.

About Teva Pharmaceutical

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
OrganisationTeva Pharmaceutical
Headquarters124 Dvora HaNevi?a St., Tel Aviv-Yafo, Israel, 6944020
IndustryDrug Manufacturers - Specialty & Generic
CEOMr. Richard D. Francis
E-voting on sharesClick here to vote

Key Management of Teva Pharmaceutical

Name

Title

Ms. Christine Fox

Executive VP of US Commercial & Head of Innovative Franchise

Mr. Richard D. Francis

President, CEO & Director

Mr. Eliyahu Sharon Kalif

Executive VP & CFO

Dr. Eric A. Hughes M.D., Ph.D.

Executive VP of Global R&D and Chief Medical Officer

Mr. Christopher J. Stevo CFA

Senior Vice President of Investor Relations & Competitive Intelligence

Kathleen Veit

Senior Vice President, Global Compliance & Ethics Officer

Mr. Brian Savage

Interim Chief Legal Officer

Mr. Evan Lippman M.B.A.

Executive Vice President of Business Development

Mr. Matthew Shields

Executive Vice President of Global Operations

Mr. Amir Weiss

Senior VP & Chief Accounting Officer

FAQs

What is Teva Pharmaceutical share price today?

Teva Pharmaceutical share price today is $39.04 as on . Teva Pharmaceutical share today touched a day high of $39.24 and a low of $38.66.

What is the 52 week high and 52 week low for Teva Pharmaceutical share?

Teva Pharmaceutical share touched a 52 week high of $39.70 on and a 52 week low of $18.21 on . Teva Pharmaceutical stock price today i.e. is trending at $39.04,which is 1.66% down from its 52 week high and 114.39% up from its 52 week low.

What is Teva Pharmaceutical's market capitalisation today?

Teva Pharmaceutical market capitalisation is $0.05T as on .

How to invest in Teva Pharmaceutical Stock (TEVA) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Teva Pharmaceutical on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Teva Pharmaceutical Shares that will get you 0.0384 shares as per Teva Pharmaceutical share price of $39.04 per share as on September 18, 2026 at 11:43 pm IST.

What is the minimum amount required to buy Teva Pharmaceutical Stock (TEVA) from India?

Indian investors can start investing in Teva Pharmaceutical (TEVA) shares with as little as ₹95.8725 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹958.73 in Teva Pharmaceutical stock (as per the Rupee-Dollar exchange rate as on ). Based on Teva Pharmaceutical share’s latest price of $39.04 as on September 18, 2026 at 11:43 pm IST, you will get 0.2561 shares of Teva Pharmaceutical. Learn more about fractional shares .

What are the returns that Teva Pharmaceutical has given to Indian investors in the last 5 years?

Teva Pharmaceutical stock has given 335.93% share price returns and 29.78% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?